JP2018507880A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018507880A5 JP2018507880A5 JP2017547148A JP2017547148A JP2018507880A5 JP 2018507880 A5 JP2018507880 A5 JP 2018507880A5 JP 2017547148 A JP2017547148 A JP 2017547148A JP 2017547148 A JP2017547148 A JP 2017547148A JP 2018507880 A5 JP2018507880 A5 JP 2018507880A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- hydrogen
- hydroxyl
- dose
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229910052739 hydrogen Inorganic materials 0.000 claims description 30
- 239000001257 hydrogen Substances 0.000 claims description 30
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 28
- 150000001875 compounds Chemical class 0.000 claims description 16
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 16
- 150000001413 amino acids Chemical class 0.000 claims description 15
- 150000003839 salts Chemical class 0.000 claims description 15
- 201000010099 disease Diseases 0.000 claims description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 208000019423 liver disease Diseases 0.000 claims description 7
- 208000024891 symptom Diseases 0.000 claims description 7
- 206010008635 Cholestasis Diseases 0.000 claims description 6
- 230000037182 bone density Effects 0.000 claims description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 4
- 230000001404 mediated effect Effects 0.000 claims description 4
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims description 3
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims description 3
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims description 3
- 206010008609 Cholangitis sclerosing Diseases 0.000 claims description 2
- 208000029725 Metabolic bone disease Diseases 0.000 claims description 2
- 206010049088 Osteopenia Diseases 0.000 claims description 2
- 208000001132 Osteoporosis Diseases 0.000 claims description 2
- 230000008468 bone growth Effects 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 230000011164 ossification Effects 0.000 claims description 2
- 201000000742 primary sclerosing cholangitis Diseases 0.000 claims description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 208000010157 sclerosing cholangitis Diseases 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 30
- 238000000034 method Methods 0.000 description 32
- 125000000217 alkyl group Chemical group 0.000 description 4
- 150000002431 hydrogen Chemical class 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562130144P | 2015-03-09 | 2015-03-09 | |
| US62/130,144 | 2015-03-09 | ||
| PCT/US2016/021344 WO2016144946A1 (en) | 2015-03-09 | 2016-03-08 | Methods for modulating bone density |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018507880A JP2018507880A (ja) | 2018-03-22 |
| JP2018507880A5 true JP2018507880A5 (enExample) | 2019-04-11 |
Family
ID=56879295
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017547148A Pending JP2018507880A (ja) | 2015-03-09 | 2016-03-08 | 骨密度を調節する方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20180042943A1 (enExample) |
| EP (1) | EP3268009A4 (enExample) |
| JP (1) | JP2018507880A (enExample) |
| KR (1) | KR20170125927A (enExample) |
| CN (1) | CN107530361A (enExample) |
| AU (1) | AU2016229906A1 (enExample) |
| CA (1) | CA2978916A1 (enExample) |
| HK (1) | HK1243646A1 (enExample) |
| IL (1) | IL254197A0 (enExample) |
| MX (1) | MX2017011399A (enExample) |
| SG (1) | SG11201707328SA (enExample) |
| WO (1) | WO2016144946A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201812382D0 (en) | 2018-07-30 | 2018-09-12 | Nzp Uk Ltd | Compounds |
| US10919162B2 (en) | 2018-12-26 | 2021-02-16 | Ford Global Technologies, Llc | Systems and methods for efficient power management of modular mobile robot platforms with replaceable batteries |
| DE102020101118A1 (de) | 2019-01-18 | 2020-07-23 | Ford Global Technologies, Llc | Mobile mehrzweckroboter und verfahren zu deren verwendung |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003223214B2 (en) * | 2002-03-01 | 2008-09-18 | Celltech R & D, Inc. | Methods to increase or decrease bone density |
| WO2003080803A2 (en) * | 2002-03-21 | 2003-10-02 | Smithkline Beecham Corporation | Methods of using farnesoid x receptor (fxr) agonists |
| CL2007003035A1 (es) * | 2006-10-24 | 2008-05-16 | Smithkline Beechman Corp | Compuestos derivados de isoxazol sustituidos, agonistas de receptores farnesoid x; procedimiento de preparacion; composicion farmaceutica que lo comprende; y uso del compuesto en el tratamiento de la obesidad, diabetes mellitus, fibrosis en organos, |
| JP2012072095A (ja) * | 2010-09-29 | 2012-04-12 | Tokyo Institute Of Technology | 骨形成促進剤 |
| ES2822375T3 (es) * | 2012-06-19 | 2021-04-30 | Intercept Pharmaceuticals Inc | Preparación de la forma no cristalina del ácido obeticólico |
| WO2014021694A1 (ko) * | 2012-08-03 | 2014-02-06 | 서울대학교 산학협력단 | 골 관련 질환 예방 및 치료를 위한 조성물 |
| HRP20180931T1 (hr) * | 2013-05-14 | 2018-10-05 | Intercept Pharmaceuticals, Inc. | 11-hidroksil-6-supstituirani-derivati žučnih kiselina i njihovi aminokiselinski konjugati kao modulatori receptora za farnezoid x |
-
2016
- 2016-03-08 KR KR1020177027942A patent/KR20170125927A/ko not_active Withdrawn
- 2016-03-08 CA CA2978916A patent/CA2978916A1/en not_active Abandoned
- 2016-03-08 AU AU2016229906A patent/AU2016229906A1/en not_active Abandoned
- 2016-03-08 SG SG11201707328SA patent/SG11201707328SA/en unknown
- 2016-03-08 HK HK18103269.8A patent/HK1243646A1/zh unknown
- 2016-03-08 US US15/556,514 patent/US20180042943A1/en not_active Abandoned
- 2016-03-08 WO PCT/US2016/021344 patent/WO2016144946A1/en not_active Ceased
- 2016-03-08 EP EP16762337.0A patent/EP3268009A4/en not_active Withdrawn
- 2016-03-08 JP JP2017547148A patent/JP2018507880A/ja active Pending
- 2016-03-08 CN CN201680022614.7A patent/CN107530361A/zh active Pending
- 2016-03-08 MX MX2017011399A patent/MX2017011399A/es unknown
-
2017
- 2017-08-29 IL IL254197A patent/IL254197A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023002662A5 (enExample) | ||
| JP2016534063A5 (enExample) | ||
| JP2013501731A5 (enExample) | ||
| JP2015514135A5 (enExample) | ||
| JP2018514534A5 (enExample) | ||
| JP2015505564A5 (enExample) | ||
| JP2015521167A5 (enExample) | ||
| JP2012507521A5 (enExample) | ||
| JP2009533356A5 (enExample) | ||
| JP2014502641A5 (enExample) | ||
| JP2020517696A5 (enExample) | ||
| JP2013521303A5 (enExample) | ||
| JP2017529389A5 (enExample) | ||
| JP2014505107A5 (enExample) | ||
| RU2014135436A (ru) | Комбинация ингибитора rtk с антиэстрогеном и ее применение для лечения рака | |
| RU2014119711A (ru) | Трициклические соединения, композиции, содержащие указанные соединения, и их применения | |
| JP2020504129A (ja) | 非アルコール性脂肪性肝炎（ｎａｓｈ）および肝線維症のための併用療法 | |
| JP2018507886A5 (enExample) | ||
| JP2018537513A5 (enExample) | ||
| JP2015535247A5 (enExample) | ||
| JP2019529460A5 (enExample) | ||
| JP2011046708A5 (enExample) | ||
| JP2017508817A5 (enExample) | ||
| JP2018507880A5 (enExample) | ||
| JP2016509601A5 (enExample) |